Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
Open Access
- 11 June 2019
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 3 (3) , 542-554
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 34 references indexed in Scilit:
- A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice modelsBlood, 2013
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Haemophilia care – past, present and future from a patient perspectiveHaemophilia, 2012
- Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns surveyHaemophilia, 2012
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importanceHaemophilia, 2009
- Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- European principles of haemophilia careHaemophilia, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Barriers to compliance with prophylaxis therapy in haemophiliaHaemophilia, 2001